Microsatellite Instability: A Complete Medical Overview

Microsatellite instability, often called MSI, is a change found in some cancers when the cells cannot reliably repair certain DNA copying errors. An MSI result can help doctors better understand a tumor, assess whether inherited Lynch syndrome may be involved, and consider appropriate treatment options.

What Is Microsatellite Instability?

Microsatellite instability (MSI) is a molecular feature that may be found when a cancer tumor is tested. Microsatellites are short, repeating sections of DNA found throughout the genome. During normal cell division, DNA must be copied accurately. Small errors can occur within these repeated sections, but the body usually corrects them through a DNA repair process called mismatch repair.

When the mismatch repair system does not work properly, copying errors can accumulate in microsatellites. This pattern is called microsatellite instability. Tumors are often described as MSI-high (MSI-H) when there is a substantial level of instability, or microsatellite stable (MSS) when this feature is not found. Some reports may also use the term MSI-low, although this category is less important in many current clinical decisions.

MSI is not an illness a person can feel, and it does not cause symptoms by itself. Instead, it is a biomarker: a measurable tumor characteristic that can provide information about how a cancer developed and how it may respond to certain treatments. It is most often identified after a biopsy or surgery has provided tumor tissue for laboratory analysis.

MSI and Mismatch Repair Deficiency

Mismatch repair is a natural quality-control system for DNA. Key mismatch repair proteins include MLH1, MSH2, MSH6, and PMS2. These proteins recognize and repair certain mistakes made as DNA is copied. If one or more of these proteins is missing or not functioning, the tumor is described as mismatch repair deficient, or dMMR.

MSI-high and dMMR are closely related, but they are measured in different ways. MSI testing looks for changes in microsatellite DNA sequences. Mismatch repair testing commonly uses immunohistochemistry (IHC), a laboratory method that checks whether the relevant repair proteins are present in tumor cells. In most cases, MSI-H and dMMR findings occur together, but doctors interpret the full pathology report rather than relying on one result alone.

Loss of mismatch repair function allows a tumor to develop many DNA changes over time. Some of these changes can create abnormal proteins that may be more recognizable to the immune system. This biological feature helps explain why MSI-H or dMMR status can be important when treatment is being considered.

Which Cancers May Be MSI-High?

Microsatellite instability is most commonly discussed in colorectal cancer and endometrial cancer, which affects the lining of the uterus. It can also be found in a smaller proportion of cancers of the stomach, small intestine, pancreas, bile ducts, ovaries, urinary tract, prostate, and other organs. The likelihood of MSI depends on the cancer type, the person’s age, and the specific features of the tumor.

Many professional guidelines support routine tumor screening for mismatch repair deficiency or MSI in colorectal and endometrial cancers. This approach can identify tumors that may have treatment implications and can also help recognize people who could benefit from assessment for inherited cancer predisposition.

An MSI-high result does not by itself describe the cancer stage, predict an individual outcome, or replace standard pathology information. Tumor type, location, grade, stage, molecular findings, overall health, and treatment history all remain important. A cancer specialist can explain what the result means in the context of the individual diagnosis.

Why MSI Can Be Related to Lynch Syndrome

Lynch syndrome is an inherited condition that increases the risk of several cancers, especially colorectal and endometrial cancers. It is caused by a harmful inherited change in one of the mismatch repair genes, most often MLH1, MSH2, MSH6, PMS2, or EPCAM. Because these genes are involved in mismatch repair, cancers related to Lynch syndrome are often dMMR or MSI-high.

However, not every MSI-high tumor is caused by Lynch syndrome. In many cases, especially some colorectal and endometrial cancers diagnosed later in life, mismatch repair deficiency develops only within the tumor and is not inherited. For example, changes that switch off the MLH1 gene in tumor cells can lead to dMMR without being passed through a family.

If tumor testing suggests a possible inherited cause, the care team may recommend genetic counseling and germline genetic testing using blood or saliva. Genetic counselors help patients understand what testing can and cannot show, how results may affect relatives, and what screening may be appropriate. A tumor test is not the same as a genetic test, so follow-up evaluation is important when indicated.

• A personal history of colorectal or endometrial cancer at a younger age may prompt further assessment.
• Multiple Lynch-associated cancers in one person can be relevant.
• A family history of related cancers, particularly across generations, may warrant discussion with a clinician or genetic counselor.

How Microsatellite Instability Is Tested

MSI testing is usually performed on a sample of cancer tissue obtained during a biopsy, surgery, or sometimes from a previous pathology specimen. The laboratory may use polymerase chain reaction (PCR) to compare selected microsatellite markers, or next-generation sequencing (NGS) to examine multiple genetic features of the tumor. Both methods can identify MSI status in appropriate samples.

Immunohistochemistry is another common first-line test. It stains the tumor tissue for the main mismatch repair proteins. If a protein is absent in tumor cells while normal cells retain it, this supports mismatch repair deficiency and can provide clues about which gene pathway may be affected. Further tumor testing may be used in certain situations to clarify whether the finding is more likely inherited or acquired.

Occasionally, a tissue sample is too small or does not contain enough tumor cells for a reliable result. The doctor may then recommend testing another specimen or using a different method. Results should be reviewed with an oncologist, pathologist, surgeon, or genetic specialist who can connect the laboratory finding with the person’s diagnosis and family history.

How MSI May Affect Cancer Treatment

MSI status can help guide treatment discussions, but it does not determine treatment on its own. For early-stage cancers, surgery, pathology findings, and the risk of recurrence remain central to planning. In some settings, MSI or dMMR status may influence decisions about chemotherapy after surgery, particularly in colorectal cancer. The meaning of a result differs by cancer type and stage.

For some advanced, recurrent, or unresectable MSI-H/dMMR cancers, immune checkpoint inhibitors may be considered. These medicines help the immune system recognize and attack cancer cells. They are used only when clinically appropriate and according to the specific cancer, its stage, previous treatments, regulatory guidance, and the patient’s overall health.

Immunotherapy can cause side effects because an activated immune system may inflame healthy tissues. Possible concerns include skin changes, diarrhea, hormone-related effects, lung inflammation, or liver inflammation, among others. Prompt reporting of new symptoms allows the oncology team to assess them early. Treatment choices should be made through an informed discussion of potential benefits, limitations, alternatives, and follow-up needs.

For international patients, Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals can assess pathology findings, coordinate genetic evaluation when appropriate, and develop cancer treatment plans based on the individual clinical situation.

When to Seek Medical Care

People do not need to seek urgent medical care because of an MSI result alone. However, anyone who has received a cancer pathology report stating MSI-high, MSI-H, dMMR, or loss of mismatch repair proteins should discuss the result with the clinician managing their care. The clinician can explain whether additional tumor analysis, genetic counseling, or changes to treatment planning are appropriate.

A medical appointment is also sensible for people with a strong family history of colorectal, uterine, ovarian, stomach, pancreatic, urinary tract, or certain other cancers, particularly when relatives were diagnosed at younger ages. Genetic counseling may be helpful even if no one in the family has yet had MSI testing.

New or persistent symptoms such as rectal bleeding, an ongoing change in bowel habits, unexplained weight loss, unusual vaginal bleeding, pelvic pain, or persistent abdominal discomfort should be assessed by a qualified clinician. These symptoms are common and can have causes other than cancer, but timely evaluation is important. Emergency care is appropriate for severe bleeding, fainting, severe abdominal pain, or other rapidly worsening symptoms.

Frequently asked questions

Is microsatellite instability the same as cancer?

No. Microsatellite instability is a biomarker found through laboratory testing of tumor tissue, not a cancer diagnosis itself. It describes a pattern of DNA changes that can occur in some cancers when mismatch repair is not working normally.

What does an MSI-high result mean?

MSI-high means the tested tumor has a high amount of instability in repeated DNA sequences. It often indicates mismatch repair deficiency and may be relevant to treatment planning and assessment for Lynch syndrome. The result needs to be interpreted alongside the cancer type, stage, pathology findings, and personal and family history.

Does MSI-high always mean Lynch syndrome?

No. Although Lynch syndrome can cause MSI-high tumors, many MSI-high cancers are caused by changes that occur only in the tumor and are not inherited. Further tumor tests and, when appropriate, germline genetic testing can help clarify the cause.

Can a blood test diagnose microsatellite instability?

MSI is most commonly assessed using tumor tissue from a biopsy or operation. Some advanced cancer testing approaches may analyze tumor DNA in blood, but tissue testing remains important in many situations. The oncology team can advise which sample and method are most suitable.

Does an MSI-high cancer respond to immunotherapy?

MSI-high or dMMR status can make some cancers more likely to be considered for immune checkpoint inhibitor treatment, particularly when cancer is advanced or cannot be removed surgically. It does not guarantee a response, and not every patient is a candidate. A specialist considers the full clinical picture before recommending treatment.

Can microsatellite instability be prevented?

MSI itself is a tumor feature and cannot usually be prevented directly. For people with Lynch syndrome, regular recommended cancer surveillance and risk-reduction discussions can help support earlier detection or prevention of certain cancers. A genetics professional can provide personalized guidance for affected individuals and families.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.